Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer’s Perspective

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a leading health issue, causing economic burden in India. Pharmacotherapy is a major cost driver in diabetic care usually funded through out of pocket expenditure; however, there has been a very limited economic evaluation evidence to guide the choice o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagepally, Bhavani Shankara, Chaikledkaew, Usa, Youngkong, Sitaporn, Anothaisintawee, Thunyarat, Thavorncharoensap, Montarat, Dejthevaporn, Charungthai, Thakkinstian, Ammarin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548256/
https://www.ncbi.nlm.nih.gov/pubmed/34712053
http://dx.doi.org/10.2147/CEOR.S328433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548256/
https://www.ncbi.nlm.nih.gov/pubmed/34712053
http://dx.doi.org/10.2147/CEOR.S328433

Ejemplares similares